CCI-001
/ PharmaMatrix Holdings
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 12, 2025
A Study of CCI-001 in Patients With Recurrent and/or Metastatic Solid Tumours
(clinicaltrials.gov)
- P1 | N=70 | Recruiting | Sponsor: PharmaMatrix Holdings Ltd | Trial completion date: May 2025 ➔ Dec 2026 | Trial primary completion date: May 2025 ➔ Dec 2026
Trial completion date • Trial primary completion date • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor
April 05, 2024
A Study of CCI-001 in Patients With Recurrent and/or Metastatic Solid Tumours
(clinicaltrials.gov)
- P1 | N=70 | Recruiting | Sponsor: PharmaMatrix Holdings Ltd | Trial completion date: May 2023 ➔ May 2025 | Trial primary completion date: May 2023 ➔ May 2025
Metastases • Trial completion date • Trial primary completion date • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor
1 to 2
Of
2
Go to page
1